Song Yi Mandra Medical Ltd ... Net Worth

The estimated Net Worth of Song Yi Mandra Medical Ltd ... is at least $10.4 Milhão dollars as of 23 August 2018. Song Ltd owns over 25,748 units of Athenex Inc stock worth over $1,032,627 and over the last 7 years Song sold ATNX stock worth over $9,411,179.

Song Ltd ATNX stock SEC Form 4 insiders trading

Song has made over 8 trades of the Athenex Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Song sold 25,748 units of ATNX stock worth $444,925 on 23 August 2018.

The largest trade Song's ever made was buying 328,637 units of Athenex Inc stock on 19 June 2017 worth over $3,615,007. On average, Song trades about 59,193 units every 29 days since 2017. As of 23 August 2018 Song still owns at least 5,163,134 units of Athenex Inc stock.

You can see the complete history of Song Ltd stock trades at the bottom of the page.

Insiders trading at Athenex Inc

Over the last 7 years, insiders at Athenex Inc have traded over $33,215,399 worth of Athenex Inc stock and bought 5,920,005 units worth $73,651,360 . The most active insiders traders include Advisors Llcperceptive Life..., Song Yi Zhang, eSong Yi Mandra Medical Ltd .... On average, Athenex Inc executives and independent directors trade stock every 12 days with the average trade being worth of $10,843. The most recent stock trade was executed by Joe Annoni on 22 February 2023, trading 625 units of ATNX stock currently worth $125.

What does Athenex Inc do?

athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. the company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. our business includes medical technology innovation centers and a unique manufacturing supply chain across both china and north america. through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.

Complete history of Song Ltd stock trades at Athenex Inc

Athenex Inc executives and stock owners

Athenex Inc executives and other stock owners filed with the SEC include:

• Johnson Lau,
  Chief Executive Officer and Chairman of the Board
• Rudolf Kwan,
  Chief Medical Officer
• Jeffrey Yordon,
  Chief Operating Officer and President, Athenex Pharmaceutical Division
• Randoll Sze,
  Chief Financial Officer
• Simon Pedder,
  Chief Business and Strategy Officer - Proprietary Products
• Jeffrey M. Yordon,
  COO & Pres of Athenex Pharmaceutical Division
• Dr. Rudolf Kwan M.D., M.B., B.S.,
  Chief Medical Officer
• Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D.,
  Chairman & CEO
• Benson Tsang,
  Independent Director
• Stephanie Davis,
  Independent Director
• Kim Campbell,
  Lead Independent Director
• Jinn Wu,
  Independent Director
• Jordan Kanfer,
  Independent Director
• John Vierling,
  Independent Director
• Manson Fok,
  Director
• Robert Spiegel,
  Director
• Daniel Lang,
  Senior Director - Corporate Development, President - Axis Therapeutics Limited
• Tim McCarthy,
  IR Contact Officer
• William Zuo,
  President, China Division
• Dr. Wing-Kai Chan,
  Deputy Chief Medical Officer of Orascovery & Src Kinase Platforms
• John W. Matthei,
  VP of HR
• Caileigh Dougherty,
  Director of Investor Relations
• Michael Smolinski Ph.D.,
  Chief Scientific Officer
• Steven J. Adams,
  Interim Chief Accounting Officer
• Daniel Lang M.D.,
  Sr. Director of Corp. Devel.
• Jacqueline Li,
  Director of Corp. Devel. & Investor Relations
• Steven Rubis,
  Sr. Director of Investor Relations
• Teresa Brophy Bair,
  Gen. Counsel, Sr. VP of Admin. & Corp. Sec.
• Dr. Allen Barnett,
  Co-Founder & Pres Emeritus
• James Zukin,
  
• Michael D Cannon,
  
• J Nick Riehle,
  Chief Financial Officer
• Antony Leung,
  
• Song Yi Zhang,
  Director
• John Koh,
  Director
• Advisors Llcperceptive Life...,
  
• Sheldon Trainor Degirolamo,
  Director
• Timothy De Vere Cook,
  See Remarks
• Teresa Brophy Bair,
  General Counsel, SVP Admin.
• Joe Annoni,
  Chief Financial Officer
• Steven J. Adams,
  Interim Chief Acct Officer
• Michael Smolinski,
  Chief Scientific Officer